Coverage
-
April 23, 2020
Stiefel Laboratories Inc. and its former chief executive have agreed to pay the U.S. Securities and Exchange Commission $37 million to end claims they defrauded investors and employees by rebuying undervalued stock before a $2.9 billion sale to GlaxoSmithKline PLC, according to documents filed Thursday in a Florida federal court.
3 other articles on this case.
View all »